Top Section/Ad
Top Section/Ad
Most recent
Weak or half-hearted response to Greenland threats will leave markets crumbling
Over the last week the US president has pushed to make homes and consumer credit more affordable but these policies risk unintended consequences
Issuance volumes may be high but demand is even higher. Credit issuers in particular should take full advantage
Hounding the Fed does not make the US bond market more attractive
More articles/Ad
More articles/Ad
More articles
-
Markets don’t like governments engaging in unnecessary economic self-harm, and after numerous warnings and cautions on its unsustainable economic policies, investors are now abandoning Turkey —Brexit Britain should beware. -
Another month, another set of headlines to scare even the most resolute of EM investors. Yet it is nearly time for Latin American primary markets to make a comeback, and issuers shouldn't let their plans get derailed.
-
Market participants should not become complacent about the battles that are still taking place over the handling of the resolution of Banco Popular, because the outcome is likely to form the blueprint for what will happen when any large European bank fails in the future.
-
The European Investment Bank has reportedly agreed to discussions which could lead to it falling under the supervisory eye of the European Central Bank, following pressure from several European Union members. But this seems more like a political refusal to give something for nothing than a move likely to improve how the supranational operates.
-
HSBC’s new app for issuers, shortly to be rolled out across the bank’s primary markets divisions and downloaded by clients directly, is a welcome change for a market that’s seen limited technological progress. It’s a clear step forward, and likely to be copied widely. But this could be the very worst outcome for issuers.
-
Hong Kong has had its first taste of a pre-revenue biotechnology stock with the listing by Ascletis Pharma. Unfortunately, the company got caught up in a wave of volatility and the shares have not fared well. It was not a good start for biotech but the sector should not be judged by this one deal, as it was just the first from a bulging IPO pipeline.
